List view / Grid view
12 January 2017 | By Niamh Marriott, Digital Editor
Topline results from this Phase IIb study to treat children with RSV with inhaled ALX-0171 are expected in the second half of 2018...
21 June 2016 | By Victoria White, Digital Content Producer
A study from University Hospital of Saint-Étienne in France reveals that mobile devices are often also contaminated by viral RNA...
4 May 2016 | By Victoria White, Digital Content Producer
The study met its primary endpoint, demonstrating the favourable safety and tolerability profile of ALX-0171 when administered daily by inhalation...
3 March 2016 | By Emmanuel Hanon, Senior Vice President, Head of Vaccines Research & Development, GSK
Here, GSK's Emmanuel Hanon discusses maternal vaccination and how it has emerged as a promising public health strategy...
13 January 2016 | By Victoria White
The RSV treatment market will rise from approximately $640 million in 2014 to over $2.3 billion by 2024, says research and consulting firm GlobalData...
19 November 2015 | By Victoria White
In the study, treatment with ALS-00876 resulted in a significant reduction of viral load and faster viral clearance versus placebo...
